Washington regulator issues a stop service order over GLP-1 compounding

Washington's Pharmacy Quality Assurance Commission placed a limited stop-service order on a pharmacy's license after finding sterile compounding and licensure failures at a facility that made GLP-1 products. The action came after the commission had already issued a statement specifically addressing semaglutide compounding, then followed up with enforcement.^[1]

The order is one of the more visible examples of state-level action against compounded versions of GLP-1 drugs, a category that includes semaglutide (sold as Ozempic, Wegovy and Rybelsus) and tirzepatide (sold as Mounjaro and Zepbound). Compounding of these drugs was allowed for a period under a federal drug-shortage rule, but that pathway closed once the Food and Drug Administration resolved the tirzepatide and semaglutide shortages. Since then, the FDA has issued guidance on what counts as compounding "essentially a copy" of an approved drug, proposed excluding these molecules from a bulk-substances list used by larger compounding pharmacies, and sent multiple rounds of warning letters to compounders and telehealth companies selling compounded GLP-1 products.^[1]

States have responded unevenly. According to a legal analysis of the state landscape, only California has written a rule stricter than federal law, requiring pharmacists to document a clinically significant, patient-specific reason for any difference from an approved drug, effective October 1, 2025. Washington and Ohio are described as "enforcers" — states whose written guidance largely restates federal law but whose boards have shown a willingness to act. Ohio's pharmacy board reported summarily suspending more than thirty clinics and medical spas since the start of 2025 and expressly prohibited compounding of the investigational peptides retatrutide and cagrilintide. Washington's stop-service order fits this same enforcement pattern.^[1]

Other states fall into different categories, the analysis says. Alabama and New Jersey have issued guidance or declaratory rulings on semaglutide compounding, often barring salt forms of the drug and requiring pharmaceutical-grade ingredients, but without the same enforcement record. Connecticut, Illinois and South Carolina have pursued compounders through consumer protection or unfair trade practices laws rather than pharmacy licensing rules. Most states, including Texas and Florida, have no GLP-1-specific rule at all and instead rely on the existing federal framework.^[1]

Why it matters for patients

For patients who use or are considering a compounded GLP-1 product, the Washington order is a reminder that oversight of these pharmacies varies significantly depending on where a patient lives or where a telehealth pharmacy is licensed. A stop-service order signals that a state regulator found problems with how a specific pharmacy prepared sterile injectable products, which can affect drug quality and safety. It does not by itself say anything about the safety of compounded semaglutide or tirzepatide products from other pharmacies.^[1]

The broader pattern described in the source material — closed drug-shortage pathways, FDA warning letters, and uneven state enforcement — means that the legal and quality landscape for compounded GLP-1 products has been narrowing since federal shortages ended. Patients weighing a compounded product versus an FDA-approved brand-name drug may find that the regulatory status of a given pharmacy is not always obvious from marketing materials alone.^[1]

What happens next

The source material does not specify further scheduled actions in Washington. It notes that California's stricter compounding rule took effect October 1, 2025, and that Ohio's board issued its GLP-1 guidance in July 2025. It also notes that the FDA removed twelve peptides from a restricted category in April 2026 and scheduled advisory committee meetings to consider some peptides for a bulk-substances list, though GLP-1 receptor agonists themselves were not included in that move. Whether other states will issue similar stop-service orders is not addressed in the available sources.^[1]